European Journal of Dermatology
MENUDevelopment of monoclonal gammopathy under biotherapy in psoriasis: a French multicenter retrospective study Volume 26, issue 1, January-February 2016
Authors
Background
1 Dermatology department,
Hôpitaux de brabois,
Bâtiment des spécialités médicales Philippe Canton,
Rue du Morvan,
54511 Vandoeuvre les Nancy,
France
Hôpitaux de brabois,
Bâtiment des spécialités médicales Philippe Canton,
Rue du Morvan,
54511 Vandoeuvre les Nancy,
France
13 Dermatology department,
CHU de Nantes
CHU de Nantes
16 Epidemiology and clinical studies department,
ESPRI, CHU Nancy
ESPRI, CHU Nancy
* Reprints
- Key words: biotherapy, monoclonal gammopathy, psoriasis
- DOI : 10.1684/ejd.2015.2700
- Page(s) : 75-81
- Published in: 2016
Biotherapies or targeted therapies are fairly new treatments indicated for moderate to severe psoriasis. The side effects appear to be mainly infectious or cancerous. The role of biotherapies in the development of a pre-cancerous condition, monoclonal gammopathy of undetermined significance (MGUS), has recently been debated in the literature.